论文部分内容阅读
子宫肌瘤是育龄期妇女最常见的良性肿瘤,治疗方法包括手术治疗和药物治疗,因其为雌激素依赖性肿瘤,绝大多数药物治疗理论均基于降低雌激素水平而达到缩小肌瘤的效果。芳香化酶抑制剂(AIs)可通过阻断雄烯二酮及睾酮向雌激素的转化,影响雌激素的生物合成,而降低体内雌激素水平。目前已有多项临床研究证实AIs在子宫肌瘤、转移性平滑肌瘤及预防促性腺激素释放激素激动剂(GnRHa)导致的不良反应方面的疗效。本研究旨在探讨芳香化酶在肌瘤组织中的表达及其对肌瘤生长的作用,对AIs在子宫肌瘤治疗中应用进行综述如下。
Uterine fibroids are the most common benign tumors of women of childbearing age, treatment methods include surgical treatment and drug treatment, because of its estrogen-dependent tumors, most of the theory of drug treatment are based on reducing estrogen levels and to achieve the effect of reducing fibroids . Aromatase inhibitors (AIs) reduce estrogen levels in the body by blocking the conversion of androstenedione and testosterone to estrogen, affecting estrogen biosynthesis. A number of clinical studies have confirmed the efficacy of AIs in the treatment of uterine leiomyoma, metastatic leiomyoma, and prophylaxis of adverse effects caused by gonadotropin-releasing hormone agonist (GnRHa). This study aimed to investigate the expression of aromatase in fibroids and its effect on myoma growth. The application of AIs in the treatment of uterine fibroids is summarized as follows.